Company intelligence / Profile preview

Faeth Therapeutics

Austin, Texas, United Statesfaeththerapeutics.com ↗

Ownership: Public · FTH
Development stage: Phase 1

Overview

Faeth's lead program, PIKTOR (combination of FTH-001/serabelisib and FTH-003/sapanisertib with paclitaxel), has shown outstanding clinical results and is now in a Phase 2 trial for patients with endometrial cancer[7].

Therapeutic areas: Oncology
Modalities: Small moleculesPrecision nutrition
Industry: Biotech

Drug pipeline

1 asset

FTH-002

Unknown

Partnerships

The GOG Foundation, Inc. (GOG-F)

Financials

Market cap: $931.1M
Total revenue: $0
Enterprise value: $745.3M

Beyond the preview

Go deeper on Faeth Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Faeth Therapeutics.

Explore the full profile